Molika Ashford

At the AACR annual meeting, investigators presented promising data across genomic and protein-based technologies, highlighting synergies that could improve performance.

Investigators reported on the firm's ctDNA residual disease assay to detect disease in colorectal patients during the ideal window for guiding therapy.

Investigators linked the presence of non-cancer mutations in the blood to worse cancer outcomes, with evidence that hematopoietic mutations can transfer to solid tumors.

The company welcomed favorable results last week from a study comparing its test to a narrower ddPCR-based approach in patients from an ongoing interventional trial.

A discussion at the Precision Medicine Tri-Con demonstrated that stakeholders are narrowing in on the challenges to realizing the promise of solid tumor MRD.

The company worked with clinical investigators to analyze outcomes data across more than 8,000 treated individuals, reconfirming the validity of its FDA-approved TMB indication.

The company analyzed MRD status in samples from a prior failed study, showing a significant benefit from the drug for ctDNA-positive patients.

Lessons from the Phase III ZEST trial could inform ongoing and future trials as they seek to use ctDNA to prove efficacy of novel adjuvant treatments.

Data from Myriad Genetics offered early validation evidence for an expanded version of its commercial test, as well as a look into clinical impact via claims data.

The research hospital is working to further validate and refine its approach, aiming to arm clinicians with a more comprehensive tool to personalize care.